Introduction of KRAS

RAS is a family of GTPase proto-oncogenes, comprising three closely related RAS isoforms: HRAS, KRAS and NRAS. From all of the RAS isoforms, KRAS is most frequently mutated. KRAS mutations are particularly frequent in the pancreatic, lung and colorectal cancers. KRAS gene is a proto-oncogene that encodes a GTP/GDP-binding protein that belongs to the GTPase RAS family. The KRAS protein acts as molecular switchs that cycle between a GDP-bound inactive state and a GTP-bound active state. KRAS protein switches between an inactive to an active form via binding to GTP and GDP, respectively. KRAS-targeted Drugs R&D Service In the formulation of KRAS integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon provides KRAS-targeted drug discovery, CMC research (API formulation), pharmacodynamics research, PK study, safety evaluation and other services.